The transcription factor signal transducer and activator of transcription-3 (STAT3) is activated by proinflammatory cytokines and circulating factors in many cell types. Synaptopodin (Synpo) is a cytoskeleton regulatory protein expressed in podocyte foot processes that regulates the dynamics of actin filaments and the stability of small GTPases. Here we show that inhibition of STAT3 signaling using the small-molecule inhibitor benzo [b]thiophene, 6-nitro-,1,1-dioxide (Stattic), or by STAT3 knockdown by small interfering RNA, caused a decrease in Synpo mRNA and protein in an immortalized mouse podocyte cell line. This loss of Synpo, which occurred in 30-80 minutes, was also seen after treatment with the translational inhibitor cycloheximide. The loss of Synpo protein after Stattic or cycloheximide treatment did not occur when podocytes were simultaneously exposed to 1-[N-[(L-3-transcarboxyoxirane-2-carbonyl)-L-leucyl]amino]-4-guanidinobutane (E-64), an inhibitor of thiol proteases such as cathepsin L. Treatment with interleukin-6 (IL-6) increased tyrosine phosphorylation of STAT3 and evoked a parallel increase in Synpo levels in podocytes. The stimulatory effect of IL-6 on Synpo was completely inhibited by pretreatment with Stattic. By contrast, 30-60-minute exposure to angiotensin II (Ang II) inhibited STAT3 signaling and concurrently reduced Synpo protein levels. The Ang II-evoked loss of Synpo was prevented by E-64 but not by inhibition of calcineurin or blockade of transient receptor potential cation channels. Inhibition of STAT3 by Stattic caused marked changes in the distribution of podocyte actin filaments, and caused a nearly complete suppression of the migration of these cells in wound assays, consistent with the loss of Synpo. Stattic treatment also caused loss of RhoA protein.
Introduction
Podocytes are terminally differentiated multipolar cells required for normal glomerular filtration. Several primary processes emanate from the podocyte cell body, wrap around the glomerular capillary, and ramify extensively, giving rise to a series of major processes. Small actin-rich foot processes extend at regular intervals from the major processes, and adhere to the external face of the glomerular capillary basement membrane (GBM) (Pavenstädt et al., 2003) . Specialized adhesions between adjacent foot processes, known as slit diaphragms (SDs), form a porous and permselective filtration barrier that is essential for normal renal function. SDs normally allow water and small solutes to pass by convective flow and diffusion, but prevent movement of substantial amounts of albumin and most other circulating proteins into the filtrate that enters the urinary space (Haraldsson et al., 2008) .
When podocytes are subjected to injury or stress, many foot processes undergo a complex morphologic change known as effacement. The foot processes initially become broader, shorter, and less organized, and SDs are lost or displaced (Le Hir et al., 2001) . Once effacement occurs, some areas of the GBM may be left uncovered as portions of the podocytes detach from the GBM (Kriz et al., 2013) . During effacement, normal actin bundles oriented along the length of the foot process (Drenckhahn and Franke, 1988; Shirato et al., 1996; Ichimura et al., 2007) are replaced by a dense network of cortical actin immediately subjacent to the GBM (Shirato et al., 1996; Kriz et al., 2013) . Foot process effacement is not necessarily associated with a loss of podocyte viability (Kriz et al., 2013) , but it is considered to be a pathologic process. The early stages of foot process effacement are rapid in onset and reversible (Seiler et al., 1975; Asanuma et al., 2005) .
Foot process effacement is associated with changes in the abundance or localization of many cytoskeletal regulatory proteins Kriz et al., 2013) . Synaptopodin (Synpo) is an actin-associated protein that is highly expressed in podocyte foot processes and in some telencephalic neurons (Mundel et al., 1997; Asanuma et al., 2005) . The normal renal isoform of Synpo interacts directly with various actin-binding Supported in part by an M. James Scherbenske award from the American Society of Nephrology to S.E.D., and by a contract from Pfizer, Inc., to S.E.D. The corresponding author had full control over the conduct of these experiments and controlled the decision to publish. dx.doi.org/10.1124/mol.114.094508.
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/calmodulin-dependent kinase II can phosphorylate Synpo, which then binds to a 14-3-3 protein (Faul et al., 2008) . The interaction with 14-3-3 confers protection from proteolytic degradation of Synpo by cathepsin L. Conversely, dephosphorylation promotes Synpo degradation by cathepsin L (Faul et al., 2008) . Synpo is widely used as a marker for differentiated podocytes, as it is not expressed in other glomerular cell types. Synpo knockout mice exhibit delayed recovery from protamine sulfate-evoked foot process effacement and lipopolysaccharideevoked nephrosis (Asanuma et al., 2005) . Moreover, combined heterozygosity for Synpo and CD2-AP leads to proteinuria and glomerulosclerosis (Huber et al., 2006) . Therefore, it is important to understand the factors that contribute to Synpo regulation in podocytes.
Here we will present evidence that signal transducer and activator of transcription-3 (STAT3) is one such factor. STAT3 is a member of a family of nearly ubiquitous structurally related transcription factors that participate in pathways activated by cytokines, growth factors, and pathogens (Schindler and Darnell, 1995) . STAT3 can be phosphorylated by non-receptor tyrosine kinases at tyrosine residue 705. Tyrosine-phosphorylated STAT3 promotes formation of homo-or heterodimers (Zhong et al., 1994) . These translocate to the nucleus, where they bind to a specific motif within promoters (Darnell, 1997) , especially in genes involved in cell growth, differentiation, angiogenesis, and inflammation (Alvarez and Frank, 2004) . STAT3 is thought to play a role in the pathogenesis of devastating glomerular diseases, including human immunodeficiency virus-associated nephropathy (HIV-AN) and collapsing glomerulonephritis (Feng et al., 2009; Dai et al., 2013; Gu et al., 2013) . These observations raise the possibility of targeting STAT3 for treatment of glomerular diseases associated with dedifferentiation and dysregulation of the podocyte cell cycle (Barisoni et al., 1999) . Several strategies are available to modify STAT3 activation in cells and tissues. For example, there are several membranepermeable inhibitors of STAT3 activation, including benzo [b] thiophene, 6-nitro-,1,1-dioxide (Stattic).
We will present evidence that Synpo expression in podocytes closely correlates with the amount of STAT3 tyrosine phosphorylation under several different conditions in which STAT3 activation is increased or decreased, and that Synpo expression is markedly and rapidly reduced in response to suppression of STAT3 activation. We also observed that inhibition of STAT3 by Stattic markedly changes the morphology of cultured podocytes and eliminates their ability to migrate.
Materials and Methods
Cell Culture Protocols, Transfection, and Chemicals. The mouse podocyte MPC-5 cell line was obtained from Dr. Peter Mundel of Harvard Medical School (Boston, MA) and cultured in RPMI 1640 medium with 10% fetal bovine serum, 1% penicillin-streptomycin, and 0.2% plasmocin. Undifferentiated cells were cultured and propagated with recombinant mouse interferon g at 33°C in humidified 5% CO 2 . To differentiate cells, interferon g was removed and cells were incubated at 37°C for 14 days. Differentiated podocytes were treated with drugs, peptides, and cytokines (further described below) for various lengths of time, as indicated in the figures. In some experiments, STAT3 or Synpo was knocked down using standard small interfering RNA (siRNA) procedures. Panels of siRNAs directed against STAT3 or Synpo, as well as nontargeted siRNAs for use in control experiments, were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and transfected into differentiated podocytes using Lipofectamine (Invitrogen, Carlsbad, CA) in serum-reduced medium according to the manufacturer's directions, as described previously (Kim et al., 2012) . Analysis of cell proteins was carried out 48 hours after transfection with the siRNAs. Stattic (Schust et al., 2006) Immunoblot Analysis. Immunoblot analysis was carried out by standard methods (Kim et al., 2012) . In brief, prior to lysis, podocytes were rinsed with ice-cold phosphate-buffered solution (PBS). Cells were lysed using a proprietary nondenaturing detergent formulation (M-PER; Thermo Scientific, Waltham, MA), and lysates were centrifuged at 12,500g for 10 minutes at 4°C. Equal amounts of samples were subjected to 10% SDS-PAGE. The gels were then blotted onto nitrocellulose membrane, blocked, and then probed with a 1:1000 dilution of primary antibodies: anti-phospho-STAT3 Y705 (GeneTex, Irvine, CA); anti-STAT3, anti-glyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH), and anti-b-actin (Cell Signaling Technology, Beverly, MA); anti-RhoA (Cytoskeleton Inc., Denver, CO); and anti-Synpo (GeneTex). The membranes were washed repeatedly and then probed with a 1:10,000 dilution of horseradish peroxidase-conjugated secondary antirabbit (Cell Signaling Technology). Signals were visualized by chemiluminescence. The resulting data were analyzed by densitometry using ImageJ software (v1.46; National Institutes of Health, Bethesda, MD). The signals obtained for each protein were normalized to signals from b-actin or GAPDH and plotted as the mean 6 S.E.M. for at least three independent experiments. In these graphs, 100% denotes signals of equal intensity. Signal from tyrosine 705-phosphorylated STAT3 was normalized to total STAT3.
Immunofluorescence Staining. Podocytes were fixed for 30 minutes with 4% paraformaldehyde in PBS, rinsed in PBS three times, and blocked/permeabilized in PBS containing 0.5% Triton X-100 and 5% bovine serum albumin. Cells were then incubated with rabbit antiSynpo overnight at 4°C. Cells were washed and then treated with Alexa Fluor 488-conjugated antirabbit antibody (Invitrogen) for 1 hour at room temperature, washed with PBS, and then treated with rhodamineconjugated phalloidin (Cytoskeleton, Inc.) to allow visualization of actin filaments. All images were collected on an Olympus FV-1000 (Olympus, Center Valley, PA) inverted stage confocal microscope with a Plan Apo N-60 1.42 numerical aperture oil-immersion objective.
RNA Extraction and Polymerase Chain Reaction. Total RNA was isolated from cultured podocyte cells using the RNeasy kit (Qiagen, Venlo, The Netherlands). Reverse transcription of RNA and amplification was performed by using a commercially available one-step reversetranscription polymerase chain reaction kit (Qiagen). After an initial hold of 20 minutes at 50°C and 10 minutes at 95°C, the samples were cycled 40 times at 95°C for 15 seconds and 60°C for 60 seconds. Target gene forward and reverse primers were designed using Primer Express 1.5 software (Applied Biosystems, Foster City, CA). Mouse GAPDH was used as an internal standard. The primers for GAPDH, synaptopodin and nephrin, were complementary to sites on opposite sides of introns, which ensured that amplification products of appropriate size were from cDNA as opposed to genomic DNA. The following sequences of oligonucleotide primers (100 nM) were used: Synpo: forward: 59ctacactgccccagtccaag39; reverse: 59atcctcg-gagtcgagagaca39 nephrin: forward: 59agctaccctgcatagccaga39; reverse: 59ggatgaca-cccgaagaaaaa39 Cell Migration Analysis. Podocytes were seeded onto 60-mm plastic culture dishes and incubated with regular media in the presence or absence of Stattic (5 mM). Wounding was induced by scratching the monolayer with a micropipette tip, and the dish was returned to the temperature-and CO 2 -controlled incubator. Phase contrast images were collected after 24 hours.
Results
Treating differentiated mouse podocytes with 5 mM Stattic for 6 hours caused a large reduction in the amounts of Synpo mRNA detected by conventional reverse-transcription polymerase chain reaction (Fig. 1A) . This method is not very quantitative, but we did not observe a comparable effect of Stattic on nephrin mRNA. More importantly, the same pattern was seen when Synpo was quantified by immunoblot ( Fig. 1, B and C) . Specifically, Stattic treatment caused a mean loss of 65% of the Synpo that could be detected by immunoblot and which was accompanied by a decrease in the amount of tyrosine 705-phosphorylated STAT3. This effect on steady-state levels of Synpo protein was quite rapid in onset and was apparent with 30-60 minutes of Stattic treatment, and did not increase with longer exposures to this inhibitor. A marked reduction of Synpo expression also occurred when STAT3 was knocked down using a specific siRNA (Fig. 1, D and E). In those experiments, control cells were treated with a nontargeted siRNA. The effectiveness of the knockdown was seen in the reduction in both total and tyrosinephosphorylated STAT3. It is always possible that a given STAT3 inhibitor could have effects on other transcription factors, especially on other members of the STAT3 family. Therefore, we examined the effects of a second structurally dissimilar inhibitor of STAT3 activation, S3I-201. This small molecule rapidly evoked a comparable loss of Synpo expression in podocytes (Supplemental Fig. 1A ). However, treatment with CAS 285986-31-4, an inhibitor of STAT5, did not produce robust effects on either Synpo or STAT3 (Supplemental Fig. 1B ). Given these results, in subsequent experiments, we used Stattic because it is one of the best attested STAT3 inhibitors. The fact that Stattic produced similar effects on Synpo mRNA and protein suggests that it acts by inhibiting biosynthesis of Synpo. Because of ongoing proteolytic degradation of Synpo in podocytes (Faul et al., 2008) , one would expect that changes in biosynthesis would have large effects on steadystate Synpo levels, and in our experiments, Stattic caused an average of 65% reduction in Synpo after 80 minutes (Fig. 2, A and B). We also observed a rapid loss of Synpo protein after inhibition of protein synthesis using the translation inhibitor cycloheximide (CHX) (Fig. 2, C and D) . The rate of Synpo loss was similar after exposure to either CHX or Stattic. Importantly, neither Stattic nor CHX caused a loss of Synpo protein when these drugs were applied for up to 80 minutes in the presence of 10 mM E-64, a membrane-permeable inhibitor of thiol proteases such as cathepsin B and cathepsin L (Hashida et al., 1980) (Fig. 2) . These results indicate that Synpo protein normally has a half-life of 30 minutes or less in cultured podocytes owing to rapid degradation by thiol proteases such as cathepsin L (Faul et al., 2008) .
Can stimulation of STAT3 signaling evoke increases in steady-state levels of Synpo above those seen at baseline? We addressed this issue using IL-6, a proinflammatory cytokine that stimulates STAT3 tyrosine phosphorylation in podocytes through activation of a glycoprotein 130-dependent signaling system Abkhezr and Dryer, 2014) . An approximately 2-fold increase in STAT3 tyrosine phosphorylation occurred in cultured podocytes within 60 minutes after the onset of treatment. This is documented again in the present study (Fig. 3) . Here, we also note that 20 ng/ml IL-6 also evoked a parallel increase in Synpo protein easily seen after 60 minutes of treatment in the same cells (Fig. 3) . Moreover, the increase in Synpo and STAT3 phosphorylation evoked by a 6-hour exposure to IL-6 was completely blocked by concomitant exposure to 5 mM Stattic (Fig. 4) . We carried out a similar set of experiments using Ang II, which we have recently shown to cause a biphasic effect on STAT3 tyrosine phosphorylation in podocytes (Abkhezr and Dryer, 2014) . With relatively brief exposures (30-60 minutes), Ang II causes inhibition of STAT3 phosphorylation, which is a direct effect on podocytes (Abkhezr and Dryer, 2014) . In most experiments, stimulation of STAT3 occurs in response to sustained exposures to Ang II (greater than 6 hours) that are mediated indirectly through secretion of an unknown factor that acts in an autocrine fashion on glycoprotein 130 (Abkhezr and Dryer, 2014) . Here, we have focused on the early inhibitory effect (Fig. 5) . We have observed that Ang II treatment for 30 minutes and 1 hour caused a reduction in STAT3 tyrosine phosphorylation that was paralleled by a loss of Synpo in the same cells (Fig. 5, A and B) . We further probed the mechanism of this inhibitory effect on Synpo. We observed that the effect of 60-minute exposure to Ang II on Synpo was completely blocked by pretreating cells with E-64, which inhibits proteolytic degradation of Synpo (Fig. 5, C and D) . Ang II continued to reduce STAT3 phosphorylation under those conditions. By contrast, pretreating cells with the calcineurin inhibitor cyclosporine A or the transient receptor potential cation channel inhibitor SKF-96365 did not protect cells from Ang II-evoked Synpo degradation (Fig. 5, C and D) . Collectively, these data unequivocally demonstrate that changes in STAT3 brought about by external signaling systems allow for dynamic up-or downregulation of Synpo expression. We should note that E-64 protects the effects of Stattic on Synpo levels, but again, cyclosporine A had no effect (Supplemental Fig. 2B) .
Previous studies have shown that Synpo plays a role in regulating actin cytoskeleton in podocytes, and thereby affects the shape and motility of these cells in vitro (Mundel et al., 1997; Asanuma et al., 2006; Faul et al., 2008) . Therefore, we asked whether Stattic treatment causes corresponding effects on podocyte behavior in vitro. We observed that Stattic treatment caused a complete inhibition of podocyte migration as assessed by a wound assay in vitro (Fig. 6, A and B) , as has been reported previously in Synpo knockdown cells . Stattic treatment also resulted in a loss of RhoA protein in podocytes, which occurred with a time course similar to its effects on Synpo (Fig. 6C) . Given its effects on Synpo, this effect of Stattic is consistent with previous studies showing that Synpo binding to RhoA protects the small GTPase from proteolytic degradation . The loss of Synpo evoked by Stattic could be detected by fluorescence microscopy (Fig. 6D) . After 3 hours in Stattic, there were also marked changes in F-actin distribution (Fig. 6D ) similar to those seen after Synpo knockdown with siRNA (Fig. 6E ). These effects are 
Discussion
In the present study, we have shown that constitutive and dynamic STAT3 signaling increases the steady-state expression of Synpo, an important cytoskeleton regulatory protein in podocytes. Inhibition or knockdown of STAT3 evoked robust reductions of Synpo transcript and protein in cultured podocytes. This pattern suggests that STAT3 stimulates Synpo biosynthesis either directly or indirectly, which may be important to maintain steady levels of a protein that undergoes constant proteolysis. We observed a rapid decline in Synpo levels after inhibition of protein synthesis using cycloheximide. Importantly, the effects on Synpo of STAT3 inhibition and protein synthesis inhibition were completely blocked by E-64, an inhibitor of thiol proteases that are known to degrade Synpo in vivo (Faul et al., 2008) . We show that Synpo levels respond dynamically to external signals, such as IL-6 and Ang II, that increase or decrease STAT3 phosphorylation, respectively, and we show that Stattic produces effects on podocyte motility, cytoskeleton, and RhoA that are entirely consistent with its effects on Synpo levels. It is worth noting that other circulating factors that are active in podocytes are capable of activating STAT3 (Reddy et al., 2007) .
A series of recent studies have convincingly implicated STAT3 in glomerular diseases in which there is effusive proliferation of glomerular epithelial cells, including HIV-AN, crescentic glomerulonephritis, and other collapsing glomerulopathies (Feng et al., 2009; Dai et al., 2013; Gu et al., 2013) . STAT3 signaling is increased in mouse and human glomerular nephritis (Arakawa et al., 2008; Dai et al., 2013) . In addition, podocyte-specific reduction of STAT3 reduces the severity of glomerular lesions in animal models of these diseases (Feng et al., 2009; Dai et al., 2013; Gu et al., 2013) . These studies have raised the possibility that STAT3 signaling could be targeted by small-molecule inhibitors, possibly as an adjunct to current therapy. One of these studies also predicted the existence of a single STAT3 binding site (TTCCTGGAA) located around 168 kb upstream of the Synpo transcription start site . Dai et al. (2013) suspected that this site is too far upstream to regulate expression of Synpo, and consequently did not pursue it further. Our data with Stattic raise the possibility that this site is functional in regulation of the Synpo gene. However, we cannot exclude that the effects of STAT3 in cultured podocytes occur as a result of heteromerization with other transcription factors that bind to different regulatory sites on the Synpo gene or elsewhere. STAT3 could also work even more indirectly-for example, by modulating expression of micro RNAs that in turn regulate expression of Synpo and other podocyte proteins (Haghikia et al., 2012) .
We observed that inhibition of STAT3 by Stattic in cultured mouse podocytes caused a redistribution of actin filaments that was accompanied by an almost complete inhibition of cell motility, as well as a fall in total RhoA. The functional effect of Stattic is therefore almost identical to what is seen after gene silencing of Synpo in the same cell line (Asanuma et al., 2005 . In this regard, Synpo prevents proteolytic degradation of RhoA, and may also affect catalytic activity of RhoA , and correspondingly, we observed that Stattic treatment results in a loss of RhoA. Synpo also affects the stability of complexes that contain IRSp53 and Cdc42 (YanagidaAsanuma et al., 2007) . Therefore, it is possible that suppression of Synpo expression can account entirely for the changes in F-actin distribution, cell shape, and cell motility that we observed here. Collectively, these results suggest that treatments or pathologic processes that cause activation of STAT3 will increase RhoA signaling in podocytes owing to increased steady-state levels of Synpo. This would be expected to cause an increase in the overall stiffness of podocyte foot processes. Within the proinflammatory milieu in which one expects STAT3 activation Atsumi et al., 2014) , increased stiffness might function to counteract increased intraglomerular pressures in early stages of the disease process (Anderson and Brenner, 1986) , or could function to prevent detachment of podocytes from the glomerular capillary (Kriz et al., 2013) . However, sustained elevations of Synpo would be expected to cause chronic RhoA activation, which over time could promote glomerulosclerosis (Zhu et al., 2011; Greka and Mundel, 2012) . Previous work has implicated STAT3 signaling in the progression of a subset of glomerular diseases in which there is dysregulation of epithelial cells within Bowman's space, leading to dedifferentiation and proliferation of podocytes, and collapse of the capillary tuft Gu et al., 2013) . Specifically, in mouse models, a podocyte-specific STAT3 knockout was protective of these diseases, such as nephrotoxic seruminduced glomerulonephritis ) and a transgenic model of HIV-AN . Notably, there was no loss of glomerular Synpo expression in mice with constitutive podocytespecific STAT3 knockdown Gu et al., 2013) . At first glance, that result seems to contradict what we have described here. One possible explanation is that the mouse podocyte cell line that we have examined in this study uses markedly different transcriptional regulatory mechanisms to control Synpo expression compared with what normally occurs in podocytes in vivo. Although we cannot exclude that possibility, we find it somewhat implausible. An alternative explanation is that constitutive knockout of STAT3 in vivo is compensated by some other transcription factor, possibly another member of the STAT family, that maintains Synpo expression in those mice.
Because STAT3 activation is implicated in glomerular diseases in which there is abnormal podocyte proliferation, it is tempting to speculate whether Synpo expression is involved in the dysregulation of podocyte cell cycle that occurs in collapsing glomerulopathies (Barisoni et al., 1999) . One possibility is that Synpo normally plays a role to prevent STAT3 activation from causing podocytes to re-enter the cell cycle, a process that cannot occur without marked rearrangement of the cytoskeleton (Narumiya and Yasuda, 2006) . On the other hand, the presence of actin-stabilizing factors such as Synpo could also contribute to the "mitotic catastrophe" that occurs when podocytes re-enter the cell cycle but fail to complete cytokinesis (Lasagni et al., 2013; Liapis et al., 2013) . To our knowledge, there has not been any in vivo experiment in which Synpo expression is artificially elevated in podocytes. There are also no reports of Synpo knockout mice in models of glomerular disease associated with podocyte proliferation. However, existing studies indicate that there is an almost total loss of Synpo and other podocyte markers in podocytes that successfully re-enter the cell cycle, at which point it is likely that many other signaling pathways are engaged (Lu et al., 2007) . Previous studies have elegantly shown that Synpo is degraded by cathepsin L (Faul et al., 2008) . In the present study, we observed a substantial loss of Synpo protein in less than 90 minutes after inhibition of translation or inhibition of STAT3. This did not occur when cells were pretreated with E-64, a membrane-permeable inhibitor of thiol proteases such as cathepsin L. Synpo therefore has an unusually high rate of turnover, much more so than actin in this cell line.
In summary, we have shown that STAT3 regulates the steadystate levels of Synpo, an important cytoskeleton regulatory protein of podocytes. The loss of STAT3 activation causes changes in cytoskeletal dynamics and cell motility consistent with the loss of Synpo. We also show that steady-state Synpo levels can change dynamically in response to circulating factors that signal through STAT3. These results may have implications for potential use of STAT3 inhibitors in therapy of glomerular diseases. 
